Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of... see more

TSXV:TELO - Post Discussion

Telo Genomics Corp > $TDSGF GAMEPLAN
View:
Post by westdakotadave on Mar 17, 2023 2:12pm

$TDSGF GAMEPLAN

$TDSGF GAMEPLAN per Feb 28, 2023 Filing (SEDAR MD&A)
 
March 2023 = Mayo SMM results have been submitted to the American Society of Clinical Oncology (ASCO) for presentation.
June 2023 = ISO 15189 approval that allows Telo to issue laboratory developed tests ("LDT") commercially.
June 2-6, 2023 = Telo at ASCO booth IH18.
June 2023 = Mayo SMM results to be submitted/published to a op-tier hematology journal (Probably the Blood Journal).
July 2023 = Launch of TeloView-MM laboratory developed tests ("LDT").
September 2023 = Anticipated Mayo results for testing to Predict Patient Resistance to Treatment.
 
Be the first to comment on this post
Telo Genomics Corp
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities